Cancer pharmacoethnicity: Ethnic differences in susceptibility to the effects of chemotherapy

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 4806-4814

  O'Donnell, Peter H ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; VINCA ALKALOID; VINCRISTINE;

ANEMIA; CANCER CHEMOTHERAPY; CARDIOTOXICITY; DIARRHEA; DRUG RESPONSE; DRUG TOLERABILITY; ETHNIC DIFFERENCE; ETHNICITY; GENETIC POLYMORPHISM; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; VOMITING;

ANTHRACYCLINES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, NEOPLASM; ETHNIC GROUPS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; VINCA ALKALOIDS;

EID: 68049140789     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-0344     Document Type: Review

References (66)

1. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008;84:417-423
2. Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 2008;84:287-294
3. Ng PC, Zhao Q, Levy S, Strausberg RL, Venter JC. Individual genomes instead of race for personalized medicine. Clin Pharmacol Ther 2008; 84:306-309
4. Tsai HJ, Choudhry S, Naqvi M, Rodriguez- Cintron W, Burchard EG, Ziv E. Comparison of three methods to estimate genetic ancestry and control for stratification in genetic association studies among admixed populations. Hum Genet 2005;118:424-433 (Pubitemid 43091213)
5. Tang H, Quertermous T, RodriguezB, et al. Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies. Am J Hum Genet 2005;76:268-275 (Pubitemid 40129553)
6. Burchard EG, Ziv E, Coyle N, et al. The importance of race and ethnic background in biomedical research and clinical practice [see comment]. N Engl J Med 2003;348:1170-1175 (Pubitemid 36337330)
7. Rosenberg NA, Pritchard JK, Weber JL, et al. Genetic structure of human populations [see comment]. Science 2002;298:2381-2385
8. Royal CD, Dunston GM. Changing the paradigm from 'race' to human genome variation. Nat Genet 2004;36:S5-7.
9. Mountain JL, Risch N. Assessing genetic contributions to phenotypic differences among 'racial' and 'ethnic' groups. Nat Genet 2004;36:S48-53.
10. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007;109:4151-4157 (Pubitemid 46743376)
11. Reigner B, Blesch K, Weidekamm E. Clinical pharmacokinetics of capecitabine. Clin Pharmacokinet 2001;40:85-104.
12. de Bono JS, Twelves CJ. The oral fluorinated pyrimidines. Invest New Drugs 2001;19:41-59.
13. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol 2006;24:2179-2187
14. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in african-american and caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 2002;94:1160-1167 (Pubitemid 34919053)
15. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006;12:5491-5495 (Pubitemid 44497265)
16. Kouwaki M, Hamajima N, Sumi S, et al. Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. Clin Cancer Res 1998;4:2999-3004. (Pubitemid 29001473)
17. Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer 2007;43:1011-1016
18. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group [see comment]. J Clin Oncol 2008;26: 2131-2138
19. Pestalozzi BC, Peterson HF, Gelber RD, et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol 1997;15:1923-1931 (Pubitemid 27209522)
20. Popat S, Chen Z, Zhao D, et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 2006;17:1810-1817 (Pubitemid 44884057)
21. Showalter SL, Showalter TN, Witkiewicz A, et al. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it timetomove forward? Cancer Biol Ther 2008;7:986-994
22. Lecomte T, FerrazJM, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5- fluorouracil-based chemotherapy. Clin Cancer Res 2004;10:5880-5888 (Pubitemid 39180969)
23. Lee JH, Park JH, Jung Y, et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 2006;5: 3085-3095 (Pubitemid 46092050)
24. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E. Mechanistic and predictive profiling of 5-Fluorouracil resistance in human cancer cells. Cancer Res 2004;64:8167-8176 (Pubitemid 39491752)
25. Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 1999;58:310-312 (Pubitemid 29300314)
26. Marsh S, Ameyaw MM, Githang'a J, Indalo A, Ofori-Adjei D, McLeod HL. Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 2000;16:528.
27. Marsh S, McLeod HL. Thymidylate synthase pharmacogenetics in colorectal cancer [see comment]. Clin Colorectal Cancer 2001;1:175-8, discussion 9-81.
28. Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, LipshultzSE . Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol 1997;15:1544-1552 (Pubitemid 27167391)
29. Hasan S, Dinh K, Lombardo F, Kark J. Doxorubicin cardiotoxicity in African Americans [see comment]. J Natl Med Assoc 2004;96:196-199 (Pubitemid 38174798)
30. Hershman D, McBride R, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 2005;23:6639-6646 (Pubitemid 46190258)
31. Fan L, Goh BC, Wong CI, et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 2008;18:621-631
32. Lal S, Wong ZW, Jada SR, et al. Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics 2007;8:567-575 (Pubitemid 46939582)
33. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53: 5629-5637
34. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006;25:1679-1691
35. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000;38:291-304.
36. Iyer L, Ratain MJ. Pharmacogenetics and cancer chemotherapy. Eur J Cancer 1998;34:1493-1499
37. Nagasubramanian R, Innocenti F, Ratain MJ. Pharmacogenetics in cancer treatment. Annu Rev Med 2003;54:437-452
38. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815-850 (Pubitemid 32385908)
39. Zanger UM, Klein K, Saussele T, Blievernicht JMHH, Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007;8: 743-759 (Pubitemid 47288975)
40. Petros WP, Hopkins PJ, Spruill S, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer. J Clin Oncol 2005;23:6117-6125 (Pubitemid 46300229)
41. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997;51:1188-1195 (Pubitemid 27186545)
42. Renbarger JL, McCammack KC, Rouse CE, Hall SD. Effect of race on vincristine-associated neurotoxicity in pediatric acute lymphoblastic leukemia patients. Pediatr Blood Cancer 2008;50:769-771
43. Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol 2006;24: 2158-2163 (Pubitemid 46630688)
44. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-smallcell lung cancer [see comment]. N Engl J Med 2005;353:123-132 (Pubitemid 41058344)
45. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell >lung cancer: results from a randomised, placebo- controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) [see comment]. Lancet 2005;366:1527-1537 (Pubitemid 41540110)
46. Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer 2006;118: 257-262 (Pubitemid 41779062)
47. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers [see comment]. J Natl Cancer Inst 2005;97:339-346 (Pubitemid 40425952)
48. Liu W, Innocenti F, Chen P, Das S, Cook EH, Jr., Ratain MJ. Interethnic difference in the allelic distribution of human epidermal growth factor receptor intron 1 polymorphism. Clin Cancer Res 2003;9:1009-1012 (Pubitemid 36323704)
49. Watanabe A, Taniguchi M, Sasaki S. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients. Anticancer Drugs 2003;14:801-807 (Pubitemid 38339784)
50. Ogawara M, Kawahara M, Hosoe S, et al. A feasibility study of paclitaxel 225 mg/m(2) and carboplatin AUC = 6 in untreated advanced non-small cell lung cancer patients in Japan. Jpn J Clin Oncol 2002;32:48-53. (Pubitemid 41288784)
51. Takei Y, Suzuki M, Ohwada M, et al. A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer. Oncol Rep 2003;10:951-955
52. Millward MJ, Boyer MJ, Lehnert M, et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients. Ann Oncol 2003;14:449-454 (Pubitemid 36367424)
53. Huang RS, Ratain MJ. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin 2009;59:42-55.
54. Frazer KA, Murray SS, Schork NJ, Topol EJ. Human genetic variation and its contribution to complex traits. Nat Rev Genet 2009;10:241-251
55. Efferth T, Volm M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol Ther 2005;107:155-176
56. McCarthy MI, Abecasis GR, Cardon LR, et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008;9:356-369 (Pubitemid 351556063)
57. Maitland ML, Ratain MJ, Cox NJ. Interpreting P values in pharmacogenetic studies: a call for process and perspective [comment]. J Clin Oncol 2007;25:4513-4515
58. LaVallie DL, Wolf FM, Jacobsen C, Buchwald D. Barriers to cancer clinical trial participation among Native elders. [summary for patients in Ethn Dis. 2008 Spring;18:236; PMID: 18507281]. Ethn Dis 2008;18:210-217
59. Huang RS, Duan S, Bleibel WK, et al. A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci USA 2007;104: 9758-9763 (Pubitemid 47175340)
60. Hartford CM, Dolan ME. Identifying genetic variants that contribute to chemotherapy-induced cytotoxicity. Pharmacogenomics 2007;8:1159-1168 (Pubitemid 47578225)
61. Duan S, Bleibel WK, Huang RS, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 2007;67:5425-5433 (Pubitemid 46997283)
62. Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007;81:427-437 (Pubitemid 47330203)
63. Huang RS, Kistner EO, Bleibel WK, Shukla SJ, Dolan ME. Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol Cancer Ther 2007;6:31-36
64. Hartford CM, Duan S, Delaney SM, et al. Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 2009;113:2145-2153
65. Polite BN, Olopade OI. Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med 2005;48:S166-75.
66. Cooper RS, Tayo B, Zhu X. Genome-wide association studies: implications for multiethnic samples. Hum Mol Genet 2008;17:R151-5.